Cancer vaccines have emerged as a powerful new tool for cancer immunotherapy.
Adjuvants are vaccine ingredients that enhance the strength, velocity, and duration of the …

In late 2020, the US Food and Drug Administration (FDA) approved a lipid-based mRNA
vaccine for the prevention of COVID-19, which has pushed this field to be more closely …

The critical challenge for cancer vaccine‐induced T‐cell immunity is the sustained activation
of antigen cross‐presentation in antigen‐presenting cells (APCs) with innate immune …

The discovery of antibiotics has saved millions of lives, but the emergence of antibiotic‐
resistant bacteria has become another problem in modern medicine. To avoid or reduce the …

Cancer vaccines exhibit specificity, effectiveness, and safety as an alternative
immunotherapeutic strategy to struggle against malignant diseases, especially with the rapid …

Recent advances in the synthesis of nanomaterials with diagnostic and therapeutic
capabilities have been rapidly reshaping the landscape of precision medicine. Impressive …

The advent of immunotherapy has revolutionized the treating modalities of cancer. Cancer
vaccine, aiming to harness the host immune system to induce a tumor‐specific killing effect …

Using nanotechnology for cancer vaccine design holds great promise because of the
intrinsic feature of nanoparticles in being captured by antigen-presenting cells (APCs) …

The past decade has witnessed the explosive development of cancer immunotherapies.
Nevertheless, low immunogenicity, limited specificity, poor delivery efficiency, and off‐target …

Engineering nanovaccines capable of targeting dendritic cells (DCs) is desperately required
to maximize antigen cross-presentation to effector immune cells, elicit strong immune …